Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation. 1988

P A Philip, and L D Lewis, and C A James, and H J Rogers
Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London Bridge, U.K.

Ifosfamide (IF) pharmacokinetics and the plasma (NBP)-alkylating activity were determined in 33 patients with different tumours after the administration of IF as single-agent chemotherapy. All subjects had been phenotyped for debrisoquine oxidation. There is a lack of correlation between the debrisoquine metabolic ratio (DMR) and either the total plasma clearance of IF (CLIF) or the AUC of the plasma NBP-alkylating activity.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P A Philip, and L D Lewis, and C A James, and H J Rogers
January 1986, Progress in clinical and biological research,
P A Philip, and L D Lewis, and C A James, and H J Rogers
June 1990, Annals of medicine,
P A Philip, and L D Lewis, and C A James, and H J Rogers
January 1991, European journal of cancer (Oxford, England : 1990),
P A Philip, and L D Lewis, and C A James, and H J Rogers
January 1991, Oncology,
P A Philip, and L D Lewis, and C A James, and H J Rogers
March 1983, British journal of clinical pharmacology,
P A Philip, and L D Lewis, and C A James, and H J Rogers
February 1982, Clinical pharmacology and therapeutics,
P A Philip, and L D Lewis, and C A James, and H J Rogers
January 1992, European journal of clinical pharmacology,
P A Philip, and L D Lewis, and C A James, and H J Rogers
November 1980, Life sciences,
P A Philip, and L D Lewis, and C A James, and H J Rogers
February 1990, British journal of clinical pharmacology,
P A Philip, and L D Lewis, and C A James, and H J Rogers
January 1991, European journal of clinical pharmacology,
Copied contents to your clipboard!